Precision BioSciences, Inc.
General ticker "DTIL" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $65.3M (TTM average)
Precision BioSciences, Inc. follows the US Stock Market performance with the rate: 38.6%.
Estimated limits based on current volatility of 3.3%: low 5.89$, high 6.30$
Factors to consider:
- Total employees count: 68 (-37.0%) as of 2025
- Company does not operate outside North America (retrieved using AI)
- Top business risk factors: Need additional capital, Product development failure, Regulatory and compliance, Manufacturing issues, Cybersecurity threats
- Price in estimated range
- Earnings for 6 months up through Q2 are close to our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [3.43$, 9.00$]
- 2026-12-31 to 2027-12-31 estimated range: [2.94$, 7.89$]
Financial Metrics affecting the DTIL estimates:
- Negative: with PPE of -0.8 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: negative Operating cash flow
- Positive: Interest expense per share per price, % of 2.58 <= 4.56
- Negative: negative Industry operating cash flow (median)
- Positive: 58.56 < Shareholder equity ratio, % of 59.74 <= 69.38
- Positive: -1.23 < Investing cash flow per share per price, % of -1.15
- Negative: Industry earnings per price (median), % of -15.99 <= 0
- Positive: -28.70 < Return on assets ratio (scaled to [-100,100]) of -23.19
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term DTIL quotes
Long-term DTIL plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $48.73MM | $68.70MM | $34.26MM |
| Operating Expenses | $92.46MM | $94.86MM | $86.41MM |
| Operating Income | $-43.74MM | $-26.16MM | $-52.15MM |
| Non-Operating Income | $1.21MM | $33.33MM | $5.54MM |
| Interest Expense | $2.23MM | $1.78MM | $1.42MM |
| R&D Expense | $53.38MM | $59.56MM | $54.17MM |
| Income(Loss) | $-42.53MM | $7.17MM | $-46.61MM |
| Other Income(Loss) | $-18.79MM | $0.00MM | $0.89MM |
| Net Income(Loss)* | $-61.32MM | $7.17MM | $-45.72MM |
| Stockholders Equity | $18.86MM | $56.39MM | $92.25MM |
| Assets | $159.78MM | $136.39MM | $154.42MM |
| Operating Cash Flow | $-84.11MM | $-58.45MM | $-65.84MM |
| Capital expenditure | $2.28MM | $0.25MM | $0.09MM |
| Investing Cash Flow | $5.83MM | $-0.21MM | $-0.63MM |
| Financing Cash Flow | $5.39MM | $50.45MM | $95.16MM |
| Earnings Per Share** | $-15.96 | $1.05 | $-3.56 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.